Abstract:Introduction: Although stem cell transplant (PBSCT) supported high dose chemotherapy can induce remission in MM patients with high risk features (e.g. high CKS1-B expression and abnormal cytogenetics) there is a high rate of relapse. Immunologic therapies can augment high dose chemotherapy by eradicating chemo-resistant disease. We have previously established that KIR-ligand mismatched NK cells from haplo-identical donors are cytotoxic to primary MM cells. In this study we investigate whether co-incubation of NK cells with irradiated K562 cells transfected with 41BBL and membrane-bound IL15 (K562-41BBL-mIL15) could expand NK cells and augment cytotoxicity to primary MM cells. Methods: Peripheral blood mononuclear cells (PBMC) of normal donors were co-cultured with irradiated K562-41BBL -mIL15 at a 1.5:1 ratio with varying concentrations of IL2 and re-stimulated on day 7. The cultures were then analyzed for proliferation, expansion, immunophenotype and cytotoxicity. Results: By testing a range of IL2 concentrations (10–300 IU/ml) we first established that 100IU of IL2/ml induced optimal proliferation in H3 thymidine uptake assays and this concentration was used in all subsequent experiments. After two weeks PBMC co-cultured with K562-41BBL-mIL15 were enriched for NK cells (93%) and contained few T cells (0.8%) compared to PBMC cultured with IL2 alone (NK cells 11.9% and T cells 58.7% respectively). In absolute numbers there was as 60-fold (±0.6) expansion of NK cells in the K562-41BBL -IL15 cultures compared to only a 1.5-fold expansion of NK cells cultured with IL2 alone. NK cells were analyzed by flow cytometry for expression of KIR2DL1, KIR2DL2/3, and KIR3DL1 pre- and post-incubation with K562-41BBL-mIL15 and we observed no change in NK immunophenotype. 51Cr release assays of expanded NK cells showed specific killing of K562 cells (84±4%), the MM cell line U266 (88±3%), and primary MM cells (58±9%), without killing of non-myeloma patient cells (PHA-blasts) or autologous cells at a ratio of 7 NK effectors to 1 target cell. Expanded NK cells achieved much higher specific lysis and at lower E:T ratios of primary MM cells when compared side-by-side with non-expanded NK cells. Conclusion: K562-41BBL-mIL15 transfectants stimulated vigorous expansion of NK cells without expanding T lymphocytes. Analysis of the KIR repertoire showed that there was no change in NK cell subpopulations after expansion. The expanded NK cells were highly active and killed patient MM cells better than non-expanded NK cells without significant lysis of normal cells. Expanded/activated NK cells may prove especially helpful in treating patients with relapsed/refractory MM who have a high tumor burden.

IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells

Expansion of NK Cells by Engineered K562 Cells Co-Expressing 4-1BBL and Mmica, Combined with Soluble IL-21.

Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27

The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors

Multiple effects of IL-21 on human NK cells in ex vivo expansion.

Expansion and Function of Human NK Cells Induced with Different Stimulating Factor Combinations Ex Vivo

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression

Human IL-15 Inhibits NK Cells Specific for Human NK-92 Cells

Interleukin-15 Improves Cytotoxicity of Natural Killer Cells Via Up-Regulating NKG2D and Cytotoxic Effector Molecule Expression As Well As STAT1 and ERK1/2 Phosphorylation.

IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs

IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells

Expansion and activation of natural killer cells with specific cytotoxicity against multiple myeloma

IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy

Stimulation with K562 Cells Transfected with 4-1Bbl and Il-15 Expands and Activates Natural Killer (nk) Cells with Specific Cytotoxicity for Multiple Myeloma (Mm)

Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

Use of Interleukin-15 for Preparation of Adherent NK Cells from Human Peripheral Blood: Comparison with Interleukin-2.

Interleukin (IL)-15 Enhances Antibody-Dependent Cellular Cytotoxicity and Natural Killer Activity in Neonatal Cells.

Characterization of Interleukin-15 Gene-Modified Human Natural Killer Cells: Implications for Adoptive Cellular Immunotherapy.

Il-27 Enhances the Survival of Tumor Antigen-Specific Cd8+T Cells and Programs Them into Il-10-Producing, Memory Precursor-Like Effector Cells